Sabra Health Care REIT (SBRA) EBITDA (2016 - 2026)

Sabra Health Care REIT's EBITDA history runs 11 years deep, the most recent figure standing at $67.8 million for Q1 2026.

• On a quarterly basis, EBITDA changed 0.35% year-over-year to $67.8 million in Q1 2026; TTM through Mar 2026 was $266.2 million, a 1.74% decrease from a year earlier, with the FY2025 full-year figure at $265.9 million, up 9.25% from the prior year.
• EBITDA grew to $67.8 million in Q1 2026 per SBRA's latest filing, from $54.9 million in the prior quarter.
• Across five years, EBITDA topped out at $92.8 million in Q2 2025 and bottomed at -$18.0 million in Q3 2022.
• The 5-year median for EBITDA is $53.6 million (2024), against an average of $50.2 million.
• Across the five-year window, EBITDA sank 146.72% in 2022 and soared 315.23% in 2024, its largest moves.
• Year by year, EBITDA stood at $31.4 million in 2022, then jumped by 52.61% to $47.9 million in 2023, then surged by 89.61% to $90.8 million in 2024, then tumbled by 39.52% to $54.9 million in 2025, then grew by 23.48% to $67.8 million in 2026.
• Per Business Quant, the three latest SBRA EBITDA figures stand at $67.8 million (Q1 2026), $54.9 million (Q4 2025), and $50.6 million (Q3 2025).